Company / R&D per Share
Vistagen Therapeutics, Inc. R&D per Share History
FY2011-FY2021 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D per Share
$0.31
FY2021
5-year range
$0.31 / $2.52
FY2017-FY2021
Trend
-69.3%
vs FY2020
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Declined from $2.52 to $0.31 over the past 4 years.
Based on SEC 10-K filings.
0.31 in FY2021 with a 10-year CAGR of -7.7%.
Declined from $2.52 to $0.31 over the past 4 years.
R&D per Share over time
Growth rates
- 3-Year CAGR
- -32.5%
- 5-Year CAGR
- -
- 10-Year CAGR
- -7.7%
Key checks
Key Insights
- In FY2021, r&d per share decreased 69.3% year-over-year.
- Peak r&d per share was recorded in FY2017.
- Lowest r&d per share in the period was in FY2014.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -7.17 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2023 | - | - |
| FY2022 | - | - |
| FY2021 | $0.31 | -69.3% |
| FY2018 | $1.02 | -59.5% |
| FY2017 | $2.52 | +1230.6% |
| FY2014 | $0.19 | -61.0% |
| FY2012 | $0.49 | -30.9% |
| FY2011 | $0.70 | - |
As of FY2021 · SEC 10-K · Updated Jun 28, 2026